Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound.

Ryu EB, Chang JM, Seo M, Kim SA, Lim JH, Moon WK.

Eur Radiol. 2014 Sep;24(9):2227-35. doi: 10.1007/s00330-014-3256-0. Epub 2014 Jun 4.

PMID:
24895040
2.

Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer.

Chang JM, Park IA, Lee SH, Kim WH, Bae MS, Koo HR, Yi A, Kim SJ, Cho N, Moon WK.

Eur Radiol. 2013 Sep;23(9):2450-8. doi: 10.1007/s00330-013-2866-2. Epub 2013 May 15.

PMID:
23673574
3.

Correlation Factors Analysis of Breast Cancer Tumor Volume Doubling Time Measured by 3D-Ultrasound.

Zhang S, Ding Y, Zhou Q, Wang C, Wu P, Dong J.

Med Sci Monit. 2017 Jun 27;23:3147-3153.

4.

18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.

Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WH, Lee SH, Kim MY, Kim JY, Seo M, Moon WK.

Eur Radiol. 2014 Mar;24(3):610-8. doi: 10.1007/s00330-013-3037-1. Epub 2013 Oct 5.

PMID:
24097303
5.

Ultrasonographic features of triple-negative breast cancer: a comparison with other breast cancer subtypes.

Yang Q, Liu HY, Liu D, Song YQ.

Asian Pac J Cancer Prev. 2015;16(8):3229-32.

6.

Surveillance of women with a personal history of breast cancer by tumour subtype.

Benveniste AP, Dryden MJ, Bedrosian I, Morrow PK, Bassett RL Jr, Yang W.

Clin Radiol. 2017 Mar;72(3):266.e1-266.e6. doi: 10.1016/j.crad.2016.09.021. Epub 2016 Oct 27.

PMID:
28341031
7.

Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.

García Fernández A, Giménez N, Fraile M, González S, Chabrera C, Torras M, González C, Salas A, Barco I, Cirera L, Cambra MJ, Veloso E, Pessarrodona A.

Breast. 2012 Jun;21(3):366-73. doi: 10.1016/j.breast.2012.03.004. Epub 2012 Apr 7.

PMID:
22487206
8.
9.

Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.

Bae MS, Seo M, Kim KG, Park IA, Moon WK.

Acta Radiol. 2015 Mar;56(3):269-75. doi: 10.1177/0284185114524197. Epub 2014 Feb 20.

PMID:
24558165
10.

Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.

Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E.

Arch Iran Med. 2016 Oct;19(10):680-686.

11.

Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.

Meattini I, Bicchierai G, Saieva C, De Benedetto D, Desideri I, Becherini C, Abdulcadir D, Vanzi E, Boeri C, Gabbrielli S, Lucci F, Sanchez L, Casella D, Bernini M, Orzalesi L, Vezzosi V, Greto D, Mangoni M, Bianchi S, Livi L, Nori J.

Eur J Surg Oncol. 2017 Apr;43(4):642-648. doi: 10.1016/j.ejso.2016.10.025. Epub 2016 Nov 17. Review.

PMID:
27889196
13.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

14.

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.

15.

Mammographic features of calcifications in DCIS: correlation with oestrogen receptor and human epidermal growth factor receptor 2 status.

Bae MS, Moon WK, Chang JM, Cho N, Park SY, Won JK, Jeon YK, Moon HG, Han W, Park IA.

Eur Radiol. 2013 Aug;23(8):2072-8. doi: 10.1007/s00330-013-2827-9. Epub 2013 Mar 20.

PMID:
23512196
16.

Brain metastases free survival differs between breast cancer subtypes.

Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Br J Cancer. 2012 Jan 31;106(3):440-6. doi: 10.1038/bjc.2011.597. Epub 2012 Jan 10.

18.

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A.

Eur J Cancer. 2009 Nov;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027. Epub 2009 Jul 28.

PMID:
19643597
19.

Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.

Subramaniam S, Bhoo-Pathy N, Taib NA, Tan GH, See MH, Jamaris S, Ho GF, Looi LM, Yip CH.

World J Surg. 2015 Oct;39(10):2450-8. doi: 10.1007/s00268-015-3133-2.

PMID:
26138872
20.

Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?

Demir L, Yigit S, Sadullahoglu C, Akyol M, Cokmert S, Kucukzeybek Y, Alacacioglu A, Cakalagaoglu F, Tarhan MO.

Asian Pac J Cancer Prev. 2014;15(22):9739-45.

Supplemental Content

Support Center